Research has demonstrated that the combination of LDH inhibitors and targeted medications (like BRAF inhibitors and MEK inhibitors) or metabolic inhibitors (like CHC) and chemotherapy medications (like doxorubicin and cisplatin) can prevent tumor growth, overcome tumor cell resistance to targeted therapy, and improve treatment efficacy (Jingtai et al., 2023; Aprile et al., 2023). The gene discussed is BRAF; the disease is neoplasm.